Genenta Science S.p.A. (NasdaqCM: GNTA)
Health Care · Biotechnology · IT
$1.15
-8.73% today · -63.9% 1Y
Genenta Science S.p.A. (NasdaqCM: GNTA) operates in the Biotechnology industry within the Health Care sector. The company is valued at $29.72M and employs 9 people.
Over the last twelve months the share price has lost 63.9%, trading between 0.55 and 10.00.
Tweenvest scores Genenta Science S.p.A. across four factors: quality 26/100. Its strongest factor is quality.
GNTA price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $29.72M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.33
- Dividend yield
- —
- Beta (5Y)
- 0.77
- 52-week high
- $10.00
- 52-week low
- $0.55
- Avg volume (3M)
- —
- Shares outstanding
- 23.59M
- Employees
- 9
- Next earnings
- —
About Genenta Science S.p.A.
Genenta Science S.p.A. is an Italian clinical-stage biotechnology firm focused on pioneering hematopoietic stem cell gene therapies to combat solid tumors. Its primary therapeutic candidate, Temferon, is currently undergoing Phase 1/2a clinical evaluation. This innovative therapy is being developed to treat glioblastoma multiforme, specifically targeting patients whose tumors exhibit an unmethylated MGMT gene promoter. Beyond this, Genenta Science is exploring Temferon's potential application in various other solid tumor types, including locally advanced hepatocellular carcinoma and intra-hepatic cholangiocarcinoma. Established in 2014, the company maintains its headquarters in Milan, Italy.
- ISIN
- US36870W1009
- Founded
- 2014
- Listed since
- Dec 15, 2021
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $265.79 | +0.48% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $442.24 | -0.36% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $148.77 | +1.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $552.85 | +0.96% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $833.56 | +0.61% |
| argenx SEENXTBR: ARGX | $63.06B | €879.20 | +1.74% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $158.83 | +14.36% |
Figures last refreshed Aug 18, 2026.